Nanomedicines in oral cancer: inspiration comes from extracellular vesicles and biomimetic nanoparticles / Yu-Ting Bai, Xue-Qiong Zhang, Xiao-Jie Chen, Gang Zhou
Oral cancer is a common life-threatening malignancy having high mortality and morbidity rates. During the treatment process, individuals unavoidably experience severe side effects. It is essential to develop safer and more effective strategies. Currently, extracellular vesicles (EVs) and biomimetic nanoparticles are nanomedicines with long-term blood circulation and lower off-target toxicity that orchestrate immune responses and accumulate specifically in tumor sites. EVs create a synergetic effect by encapsulating drugs and collaborating with naturally loaded elements in the EVs. Biomimetic nanoparticles retain the characteristic features of the synthetic nanocarriers and inherit the intrinsic cell membrane functionalities. This review outlines the properties, applications, challenges, pros and cons of EVs and biomimetic nanoparticles, providing novel perspectives on oral cancer. Plain language summary This review explains how extracellular vesicles (EVs) and biomimetic nanoparticles are emerging as nanomedicines applied in oral cancer. EVs are phospholipid bilayer vesicles, mainly including exosomes and microvesicles, responsible for intercellular communication and cargo transport. EVs can carry RNA, metabolites and other molecular payloads. Biomimetic nanomedicines are synthetic nanoparticles coated with the parent or host cell membrane to escape the immune system and elevate targeting ability. Various cell membranes have been used for camouflaging nanoparticles, such as red blood cells, white blood cells, platelets, mesenchymal stem cells and cancer cell membranes.During the treatment process, individuals unavoidably experience severe side effects. It is essential to develop safer and more effective strategies. Currently, EVs and biomimetic nanoparticles are nanomedicines with long-term blood circulation and lower off-target toxicity that orchestrate immune responses and accumulate specifically in tumor sites. EVs create a synergetic effect by encapsulating drugs and collaborating with naturally loaded elements in the EVs. Biomimetic nanoparticles retain the characteristic features of the synthetic nanocarriers and inherit the intrinsic cell membrane functionalities. This review outlines the properties, applications, challenges, pros and cons of EVs and biomimetic nanoparticles, providing novel perspectives on oral cancer. . Graphical abstract Outlines of extracellular vesicles and biomimetic nanomedicines in oral cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bai, Yu-Ting [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Biomimetic nanoparticles |
|---|
| Umfang: |
1 Online-Ressource (18 p) |
|---|
| doi: |
10.2217/nnm-2022-0142 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011096012 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011096012 | ||
| 003 | DE-627 | ||
| 005 | 20230713210643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2022-0142 |2 doi | |
| 035 | |a (DE-627)KFL011096012 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2022-0142 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Bai, Yu-Ting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanomedicines in oral cancer: inspiration comes from extracellular vesicles and biomimetic nanoparticles |c Yu-Ting Bai, Xue-Qiong Zhang, Xiao-Jie Chen, Gang Zhou |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (18 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Oral cancer is a common life-threatening malignancy having high mortality and morbidity rates. During the treatment process, individuals unavoidably experience severe side effects. It is essential to develop safer and more effective strategies. Currently, extracellular vesicles (EVs) and biomimetic nanoparticles are nanomedicines with long-term blood circulation and lower off-target toxicity that orchestrate immune responses and accumulate specifically in tumor sites. EVs create a synergetic effect by encapsulating drugs and collaborating with naturally loaded elements in the EVs. Biomimetic nanoparticles retain the characteristic features of the synthetic nanocarriers and inherit the intrinsic cell membrane functionalities. This review outlines the properties, applications, challenges, pros and cons of EVs and biomimetic nanoparticles, providing novel perspectives on oral cancer. Plain language summary This review explains how extracellular vesicles (EVs) and biomimetic nanoparticles are emerging as nanomedicines applied in oral cancer. EVs are phospholipid bilayer vesicles, mainly including exosomes and microvesicles, responsible for intercellular communication and cargo transport. EVs can carry RNA, metabolites and other molecular payloads. Biomimetic nanomedicines are synthetic nanoparticles coated with the parent or host cell membrane to escape the immune system and elevate targeting ability. Various cell membranes have been used for camouflaging nanoparticles, such as red blood cells, white blood cells, platelets, mesenchymal stem cells and cancer cell membranes.During the treatment process, individuals unavoidably experience severe side effects. It is essential to develop safer and more effective strategies. Currently, EVs and biomimetic nanoparticles are nanomedicines with long-term blood circulation and lower off-target toxicity that orchestrate immune responses and accumulate specifically in tumor sites. EVs create a synergetic effect by encapsulating drugs and collaborating with naturally loaded elements in the EVs. Biomimetic nanoparticles retain the characteristic features of the synthetic nanocarriers and inherit the intrinsic cell membrane functionalities. This review outlines the properties, applications, challenges, pros and cons of EVs and biomimetic nanoparticles, providing novel perspectives on oral cancer. . Graphical abstract Outlines of extracellular vesicles and biomimetic nanomedicines in oral cancer | ||
| 653 | |a biomimetic nanoparticles | ||
| 653 | |a cell membrane-based nanoparticles | ||
| 653 | |a extracellular vesicles | ||
| 653 | |a nanomedicine | ||
| 653 | |a oral cancer | ||
| 700 | 1 | |a Zhang, Xue-Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiao-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Gang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2022-0142 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||